Literature DB >> 30734106

Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Sylvia E Perez1,2, Jennifer C Miguel1, Bin He1, Michael Malek-Ahmadi3, Eric E Abrahamson4,5, Milos D Ikonomovic4,5, Ira Lott6, Eric Doran6, Melissa J Alldred7,8, Stephen D Ginsberg7,8,9, Elliott J Mufson10.   

Abstract

Although, by age 40, individuals with Down syndrome (DS) develop amyloid-β (Aβ) plaques and tau-containing neurofibrillary tangles (NFTs) linked to cognitive impairment in Alzheimer's disease (AD), not all people with DS develop dementia. Whether Aβ plaques and NFTs are associated with individuals with DS with (DSD +) and without dementia (DSD -) is under-investigated. Here, we applied quantitative immunocytochemistry and fluorescent procedures to characterize NFT pathology using antibodies specific for tau phosphorylation (pS422, AT8), truncation (TauC3, MN423), and conformational (Alz50, MC1) epitopes, as well as Aβ and its precursor protein (APP) to frontal cortex (FC) and striatal tissue from DSD + to DSD - cases. Expression profiling of single pS422 labeled FC layer V and VI neurons was also determined using laser capture microdissection and custom-designed microarray analysis. Analysis revealed that cortical and striatal Aβ plaque burdens were similar in DSD + and DSD - cases. In both groups, most FC plaques were neuritic, while striatal plaques were diffuse. By contrast, FC AT8-positive NFTs and neuropil thread densities were significantly greater in DSD + compared to DSD -, while striatal NFT densities were similar between groups. FC pS422-positive and TauC3 NFT densities were significantly greater than Alz50-labeled NFTs in DSD + , but not DSD - cases. Putaminal, but not caudate pS422-positive NFT density, was significantly greater than TauC3-positive NFTs. In the FC, AT8 + pS422 + Alz50, TauC3 + pS422 + Alz50, pS422 + Alz50, and TauC3 + pS422 positive NFTs were more frequent in DSD + compared to DSD- cases. Single gene-array profiling of FC pS422 positive neurons revealed downregulation of 63 of a total of 864 transcripts related to Aβ/tau biology, glutamatergic, cholinergic, and monoaminergic metabolism, intracellular signaling, cell homeostasis, and cell death in DSD + compared DSD - cases. These observations suggest that abnormal tau aggregation plays a critical role in the development of dementia in DS.

Entities:  

Keywords:  Amyloid; Dementia; Down syndrome; Frontal cortex; Microarray; Striatum; Tau

Mesh:

Year:  2019        PMID: 30734106      PMCID: PMC6541490          DOI: 10.1007/s00401-019-01965-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  138 in total

1.  Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.

Authors:  Sylvia E Perez; Damianka P Getova; Bin He; Scott E Counts; Changiz Geula; Laurent Desire; Severine Coutadeur; Helene Peillon; Stephen D Ginsberg; Elliott J Mufson
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

2.  Dementia diagnostic criteria in Down syndrome.

Authors:  Rory Sheehan; Amanda Sinai; Nick Bass; Pippa Blatchford; Ingrid Bohnen; Simon Bonell; Ken Courtenay; Angela Hassiotis; Therese Markar; Jane McCarthy; Kamalika Mukherji; Asim Naeem; Dimitrios Paschos; Natalia Perez-Achiaga; Vijaya Sharma; David Thomas; Zuzana Walker; Andre Strydom
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

3.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

4.  Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43).

Authors:  D M Mann; T Iwatsubo
Journal:  Neurodegeneration       Date:  1996-06

5.  Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Authors:  C A Lemere; J K Blusztajn; H Yamaguchi; T Wisniewski; T C Saido; D J Selkoe
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

6.  Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies.

Authors:  E Sontag; V Nunbhakdi-Craig; G Lee; R Brandt; C Kamibayashi; J Kuret; C L White; M C Mumby; G S Bloom
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

7.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

Review 8.  Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior.

Authors:  Marina R Picciotto; Michael J Higley; Yann S Mineur
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

9.  HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease.

Authors:  L Mahady; M Nadeem; M Malek-Ahmadi; K Chen; S E Perez; E J Mufson
Journal:  Neuropathol Appl Neurobiol       Date:  2018-10-28       Impact factor: 8.090

10.  Regional analysis of striatal and cortical amyloid deposition in patients with Alzheimer's disease.

Authors:  Kenji Ishibashi; Kiichi Ishiwata; Jun Toyohara; Shigeo Murayama; Kenji Ishii
Journal:  Eur J Neurosci       Date:  2014-06-02       Impact factor: 3.386

View more
  17 in total

Review 1.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

2.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

3.  Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome.

Authors:  Emma C Utagawa; David G Moreno; Kristian T Schafernak; Nicoleta C Arva; Michael H Malek-Ahmadi; Elliott J Mufson; Sylvia E Perez
Journal:  Acta Neuropathol Commun       Date:  2022-06-08       Impact factor: 7.578

Review 4.  Alzheimer's disease associated with Down syndrome: a genetic form of dementia.

Authors:  Juan Fortea; Shahid H Zaman; Sigan Hartley; Michael S Rafii; Elizabeth Head; Maria Carmona-Iragui
Journal:  Lancet Neurol       Date:  2021-11       Impact factor: 59.935

5.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

6.  Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.

Authors:  Sarah Gourmaud; Haochang Shou; David J Irwin; Kimberly Sansalone; Leah M Jacobs; Timothy H Lucas; Eric D Marsh; Kathryn A Davis; Frances E Jensen; Delia M Talos
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

Review 7.  Epileptic Mechanisms Shared by Alzheimer's Disease: Viewed via the Unique Lens of Genetic Epilepsy.

Authors:  Jing-Qiong Kang
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

8.  Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer's Disease.

Authors:  Melissa J Alldred; Sai C Penikalapati; Sang Han Lee; Adriana Heguy; Panos Roussos; Stephen D Ginsberg
Journal:  Mol Neurobiol       Date:  2021-07-14       Impact factor: 5.682

Review 9.  Further understanding the connection between Alzheimer's disease and Down syndrome.

Authors:  Heather M Snyder; Lisa J Bain; Adam M Brickman; Maria C Carrillo; Anna J Esbensen; Joaquin M Espinosa; Fabian Fernandez; Juan Fortea; Sigan L Hartley; Elizabeth Head; James Hendrix; Priya S Kishnani; Florence Lai; Patrick Lao; Cynthia Lemere; William Mobley; Elliott J Mufson; Huntington Potter; Shahid H Zaman; Ann-Charlotte Granholm; H Diana Rosas; Andre Strydom; Michelle Sie Whitten; Michael S Rafii
Journal:  Alzheimers Dement       Date:  2020-06-16       Impact factor: 16.655

10.  Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome.

Authors:  Xu-Qiao Chen; Zhuo Xing; Quang-Di Chen; Richard J Salvi; Xuming Zhang; Benjamin Tycko; William C Mobley; Y Eugene Yu
Journal:  Front Aging Neurosci       Date:  2021-07-01       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.